Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
1. An isolated nucleic acid encoding a biotin binding immune receptor (BBIR), wherein the BBIR comprises an extracellular label binding domain comprising a dimerized avidin domain, a transmembrane domain, a T cell receptor signaling domain, wherein the label binding domain binds to a biotinylated antigen, and further wherein the nucleic acid comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 11, 12 and 13.
2. The isolated nucleic acid of claim 1 , wherein the biotinylated antigen is selected from the group consisting of a tumor antigen, a self-antigen, a viral antigen, and any combination thereof.
3. A cell comprising a nucleic acid encoding a biotin binding immune receptor (BBIR), wherein the BBIR comprises an extracellular label binding domain comprising a dimerized avidin domain, a transmembrane domain, a T cell receptor signaling domain, wherein the label binding domain binds to a biotinylated antigen, and further wherein the nucleic acid comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 11, 12 and 13.
4. The cell of claim 3 , wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
5. The cell of claim 3 , wherein the cell is activated when the label binding domain binds to its corresponding biotinylated antigen.
6. A vector comprising a nucleic acid encoding a biotin binding immune receptor (BBIR), wherein the BBIR comprises an extracellular label binding domain comprising a dimerized avidin domain, a transmembrane domain, a T cell receptor signaling domain, wherein the label binding domain binds to a biotinylated antigen, and further wherein the nucleic acid comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 11, 12 and 13.